Lakefront Biotherapeutics NV GLPGF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 85.75% | -99.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 85.75% | -99.28% | |||
| Cost of Revenue | -3.63% | -66.71% | |||
| Gross Profit | 23.41% | -103.71% | |||
| SG&A Expenses | -36.99% | 10.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -42.68% | 96.61% | |||
| Total Operating Expenses | -21.22% | -34.77% | |||
| Operating Income | 32.10% | -108.08% | |||
| Income Before Tax | -85.65% | -98.21% | |||
| Income Tax Expenses | -0.61% | -89.44% | |||
| Earnings from Continuing Operations | -86.08% | -98.22% | |||
| Earnings from Discontinued Operations | -72.93% | 277.56% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -85.53% | -98.14% | |||
| EBIT | 32.10% | -108.08% | |||
| EBITDA | 24.76% | -106.96% | |||
| EPS Basic | -85.55% | -98.14% | |||
| Normalized Basic EPS | 43.72% | -103.13% | |||
| EPS Diluted | -85.59% | -98.14% | |||
| Normalized Diluted EPS | 43.86% | -103.13% | |||
| Average Basic Shares Outstanding | 0.04% | -0.05% | |||
| Average Diluted Shares Outstanding | 0.25% | -0.07% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||